Geode Capital Management LLC Has $6.98 Million Stake in Bioventus Inc. $BVS

Geode Capital Management LLC lifted its stake in Bioventus Inc. (NYSE:BVS) by 13.1% in the second quarter, HoldingsChannel.com reports. The firm owned 1,054,903 shares of the company’s stock after purchasing an additional 122,137 shares during the quarter. Geode Capital Management LLC’s holdings in Bioventus were worth $6,984,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Bioventus by 7.2% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,048 shares of the company’s stock valued at $211,000 after acquiring an additional 1,538 shares during the period. EntryPoint Capital LLC lifted its position in Bioventus by 7.8% during the 1st quarter. EntryPoint Capital LLC now owns 28,371 shares of the company’s stock valued at $260,000 after purchasing an additional 2,048 shares during the period. Harbor Capital Advisors Inc. boosted its stake in shares of Bioventus by 12.0% in the 2nd quarter. Harbor Capital Advisors Inc. now owns 24,482 shares of the company’s stock valued at $162,000 after purchasing an additional 2,615 shares during the last quarter. EP Wealth Advisors LLC grew its position in shares of Bioventus by 24.1% during the 1st quarter. EP Wealth Advisors LLC now owns 17,490 shares of the company’s stock worth $160,000 after buying an additional 3,394 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Bioventus by 35.6% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 17,181 shares of the company’s stock worth $157,000 after buying an additional 4,513 shares during the last quarter. Institutional investors own 62.94% of the company’s stock.

Bioventus Trading Down 7.0%

Shares of NYSE BVS opened at $7.09 on Friday. Bioventus Inc. has a fifty-two week low of $5.81 and a fifty-two week high of $11.89. The firm has a market capitalization of $586.79 million, a P/E ratio of -11.62 and a beta of 0.79. The company has a debt-to-equity ratio of 1.85, a current ratio of 1.41 and a quick ratio of 0.99. The company’s 50 day simple moving average is $7.08 and its 200 day simple moving average is $6.93.

Insider Buying and Selling at Bioventus

In other news, Director Michelle Mcmurry-Heath sold 17,701 shares of the firm’s stock in a transaction on Friday, November 7th. The stock was sold at an average price of $7.42, for a total value of $131,341.42. Following the transaction, the director directly owned 56,997 shares in the company, valued at $422,917.74. This trade represents a 23.70% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 33.00% of the stock is currently owned by company insiders.

About Bioventus

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.